Clinical trial
GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally…
NCT00084643 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00084643 |
|---|---|
| Title | GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors |
| Official title | A Phase I Study of GTI-2040 in Combination With Oxaliplatin and Capecitabine in Patients With Advanced Metastatic Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug, Other |
| Interventions | GTI-2040, oxaliplatin, capecitabine, pharmacological study, laboratory biomarker analysis |
| Enrollment | 20 |
| Start date | May 1, 2004 |
| Primary completion | Apr 1, 2008 |
| First posted | Jun 11, 2004 |
| Last update posted | Mar 27, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: